NCT Research

CCRP Upper GI

Expertise

The Upper Gastrointestinal Oncology Program is a key focus of NCT.  The surgical department is one of the largest centre for esophageal and gastric cancer in Europe.

The program is well established within national and international clinical trials in the perioperative and metastatic setting. Within the last 3 years more than 15 clinical trials in phase I/II and phase III setting have been conducted in the perioperative and metastatic setting, among those several mono- and multicenter investigator-initiated trials financed by third-party funds.

One focus of the group is the optimization of perioperative therapy in locally advanced upper GI cancer involving endoscopic, radiological and nuclearmedical methods. Currently the OptiTreat trial focuses on early endoscopic-guided response to neoadjuvant treatment. In metastatic setting the efficacy of a maintenance therapy is explored in the MATEO trial. A controlled trial incooporating carbon ion irradiation in patients with upper GI cancer is in preparation.

Translational analyses aim for the identification of molecular lesions that mediate early recurrence, tumor progression and response or resistance to systemic and radiation therapies using next generation sequencing technologies (cooperation within the HIPO/POP program).  Another focus lies on the immunological response of the host, aiming to promote the establishment of immunotherapeutics for upper GI cancer.

CCRP Upper GI
 
  • Department of Surgery
  • Department of Medical Oncology
  • Department of Gastroenterology
  • Department of Radiooncology
  • Department of Radiology
  • Department of Nuclear Medicine
  • Department of Pathology
  • NCT Social Services
  • NCT Immunotherapy Group (Prof. Dr. D. Jäger, Dr. N. Halama, Dr. I. Zörnig)
  • AG Glimm (Applied Stem Cell Biology )
  • Upper GI surgical oncology group (Prof. Ott)
  • Dept. Of Pathology Predictive Pathology and Biomarker Validation Group (Prof. Dr. W. Weichert)
  • Whole Slide Section Immune Cell Quantification
  • Multiplex Protein Quantification from Tissue Sections plus Laser Microdissection
  • Antibody-Profiling of Tumor-associated Antigens in Serum and Tissue
  • Next generation sequencing technologies (HIPO/POP consortium)
  • Mutation analysis of gastric cancer to define subgroups and predict disease recurrence (Prof. Glimm, Prof. Ott).
  • Immune cell quantification and microenvironment characterization in esophageal cancer (Prof. Ott/ Jäger/Weichert)
  • Identification of gastric cancer subgroups with response to palliative treatment (Prof. Jäger, Dr. Haag)

  • German Cancer Aid (Weichert)
  • Personalized Oncology Program (POP) DKFZ/NCT
  • An Investigator-initiated trial (OptiTreat, PI Prof. Dr. K. Ott, Department of Surgery) to evaluate to role of early endoscopic guided response assessment during neoadjuvant chemotherapy for locally advanced esophagogastric cancer.  Financial Grant by the German Society for Surgery. Recruitment will start in Q3/2014
  • An investigator-initiated multicenter phase II trial to evaluate the concept of a maintenance therapy in metastastic esophagogastric cancer (MATEO trial, LKP Dr. G. M. Haag, in Cooperation with the Arbeitsgemeinschaft Internistische Onkologie within the German Cancer Society, Deutsche Krebsgesellschaft).. Recruitment will start in Q3/2014
  • Identification of molecularly defined subgroups in gastric cancer and their prognostic impact on disease recurrence using next generation sequencing (HIPO/POP program, Dr. C. Heining, Prof. Dr. K. Ott, Dr. Dr. C. Springfeld, Prof. Dr. H. Glimm)
  • Establishment of a  gene-expression based prognostic score for an individualized therapy in gastric cancer (Prof. Dr. K. Ott, financial grant by Federal Ministry of Education and Research) 
  1. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Müller-Quernheim J, Wullich B, Keck B, Graf N, Reichrath J, Vogel B, Nebel A, Jager SU, Staehler P, Amarantos I, Boisguerin V, Staehler C, Beier M, Scheffler M, Büchler MW, Wischhusen J, Haeusler SF, Dietl J, Hofmann S, Lenhof HP, Schreiber S, Katus HA, Rottbauer W, Meder B, Hoheisel JD, Franke A, Meese E. Toward the blood-borne miRNome of human diseases. Nat Methods. 2011;8:841-3
  2. Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19:2119-27.
  3. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ,
    Siewert JR, zum Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F, Krause BJ. Molecular imaging of proliferation and Glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol. 2011;18:3316-23.
  4. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jäger D, Münter MW.  BMC Cancer. 2011;11:266
  5. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis.
    Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K, Siewert JR, Ott K.
    Gastric Cancer. 2013 Sep 1. [Epub ahead of print]